epirubicin has been researched along with Diffuse Large B-Cell Lymphoma in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (18.60) | 18.2507 |
| 2000's | 21 (48.84) | 29.6817 |
| 2010's | 13 (30.23) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kuittinen, O; Kuitunen, H; Tokola, S; Turpeenniemi-Hujanen, T | 1 |
| Jantunen, E; Kuittinen, O; Peroja, P; Prusila, REI; Turpeenniemi-Hujanen, T | 1 |
| Stathis, A; Zucca, E | 1 |
| Li, LF; Liu, XM; Ren, XB; Wang, HQ | 1 |
| Aisimitula, A; Fu, L; Huang, Q; Li, Y; Mao, M; Nie, Y; Wang, X; Yimamu, M; Zhang, X | 1 |
| Bai, B; Cai, QC; Cai, QQ; Gao, Y; Guo, Y; Huang, HQ; Lin, ZX; Wang, XX | 1 |
| Cao, C; Kai, S; Liu, T; Wang, L; Xiang, B; Zhu, H | 1 |
| Avilès, A; Huerta-Guzmàn, J; Nambo, MJ; Neri, N; Silva, L | 1 |
| Abderrahim, K; Asma, A; Badreddine, S; Bechir, A; Haifa, R; Nesrine, A; Yosra, BY | 1 |
| Bellaaj, H; Ben Salah, H; Daoud, J; Elloumi, M; Frikha, M; Ghorbel, L; Krichen, MS | 1 |
| Bhartia, S; Proctor, SJ; Sieniawski, M; Wilkinson, J | 1 |
| Avilés, A; Cleto, S; Huerta-Guzmán, J; Nambo, MJ; Neri, N | 1 |
| Ali, ZB; Ben Othmen, T; Bouaouina, N; Daoud, J; Elloumi, M; Ghannem, H; Laatiri, MA; Maalej, M; Meddeb, B; Msadek, F; Toumi, N | 1 |
| Cunningham, D; Hawkes, EA; Okines, AF; Plummer, C | 1 |
| Alvarez, I; Arcari, A; Baldini, L; Chiappella, A; Di Rocco, A; Federico, M; Fragasso, A; Gobbi, PG; Ilariucci, F; Liberati, AM; Luminari, S; Mammi, C; Marcheselli, L; Mazza, P; Merli, F; Musso, M; Rossi, G; Salvi, F; Stelitano, C; Tucci, A | 1 |
| Chen, LP; Lin, SJ; Yu, MS | 1 |
| Chang, WL; Chao, TC; Gau, JP; Liu, YC | 1 |
| Avilés, A; Calva, A; Fernández, R; Huerta-Guzmán, J; Nambo, MJ; Neri, N | 1 |
| Avilés, A; Castañeda, C; Cleto, S; Fernándezb, R; González, M; Nambo, MJ; Neri, N; Pérez, F; Talavera, A | 1 |
| Annunziata, M; Copia, C; D'Amico, MR; De Simone, M; Ferrara, F; Mele, G; Palmieri, S; Pocali, B; Schiavone, EM; Viola, A | 1 |
| Angelucci, E; Baldini, L; Boccomini, C; Brugiatelli, M; Cabras, MG; Calvi, R; Ciccone, G; Deliliers, GL; Federico, M; Gallo, E; Genua, A; Levis, A; Liberati, AM; Parvis, G; Pavone, E; Salvi, F; Sborgia, M; Vitolo, U | 1 |
| Broglia, C; Corazza, GR; Federico, M; Gobbi, PG; Lambelet, P; Lombardo, M; Luminari, S; Mammi, C; Merli, F; Polimeno, G; Riezzo, A; Rovati, A; Valentino, F | 1 |
| Ambrosetti, A; Andreoli, A; Canal, F; Chilosi, M; Krampera, M; Lestani, M; Parolini, C; Pizzolo, G; Visco, C | 1 |
| Aurran, T; Biron, P; Bouabdallah, R; Boulat, O; Chabannon, C; Chetaille, B; Coso, D; Esterni, B; Gastaut, JA; Ivanov, V; Maraninchi, D; Rey, J; Schiano de Collela, JM; Sebban, C; Stoppa, AM; Xerri, L | 1 |
| Kimura, M; Kobayashi, T; Miyazaki, K; Nishikawa, H; Ogawa, S; Shiku, H; Tawara, I; Ueno, S; Yamaguchi, M | 1 |
| Leonard, JP; Siegel, AB | 1 |
| Baldini, L; Bertini, M; Botto, B; Cabras, G; Di Vito, F; Federico, M; Gallo, E; Liberati, AM; Luminari, S; Marcheselli, L; Merli, F; Mozzana, R; Naglieri, E; Orsucci, L; Pennese, E; Polimeno, G; Vitolo, U | 1 |
| Doglioni, C; Dognini, GP; Ferreri, AJ; Patriarca, C; Ponzoni, M; Verona, C | 1 |
| Koizumi, K; Kondo, M; Minauchi, K; Mukai, M; Odani, T; Takada, A | 1 |
| Avilés, A; Castañeda, C; Cleto, S; Contreras, M; Huerta-Guzmán, J; Murillo, E; Nambo, MJ; Neri, N | 1 |
| Avilés, A; Castañeda, C; Cleto, S; Contreras, M; González, M; Huerta-Guzmàn, J; Murillo, E; Nambo, MJ; Neri, N; Talavera, A | 1 |
| Bu, Q; Cai, QQ; Gao, Y; Guan, ZZ; Huang, HQ; Jiang, WQ; Lin, XB; Pan, ZH; Wang, BF; Xia, ZJ; Xu, RH | 1 |
| Alatriste, S; Avilés, A; Delgado, S; Díaz-Maqueo, JC; Nambo, MJ | 1 |
| Avilés, A; Díaz-Maqueo, JC; García, EL; Nambo, MJ; Talavera, A | 1 |
| Connors, JM; Hoskins, P; Howdle, S; Klasa, R; Klimo, P; O'Reilly, SE; Stuart, DS | 1 |
| Avilés, A; Calva, A; Díaz-Maqueo, JC; Huerta-Guzmán, J; Talavera, A; Vásquez, E | 1 |
| Fazeny, B; Fridrik, MA; Greil, R; Hausmaninger, H; Helm, W; Hudec, M; Klocker, J; Krieger, O; Neubauer, M; Oppitz, P; Pont, J; Radaszkiewicz, T; Simonitsch, I; Stöger, M | 1 |
| Hayashi, T; Mori, S; Nomura, T; Nonaka, Y; Ogawa, M; Suzuki, T | 1 |
| Dalay, N; Inanç, S; Onat, H; Saip, P; Yazici, H | 1 |
| Chim, CS; Kwong, YL; Lee, CK; Liang, R; Lie, AK | 1 |
| Egami, K; Maeda, S; Matsuda, T; Okihama, Y; Onda, M; Wada, M; Yoshioka, M | 1 |
| Angus, B; Carey, PJ; Conn, J; Culligan, D; Haynes, A; Iqbal, A; Jackson, GH; Lennard, AL; Leonard, RC; Lucraft, H; Proctor, SJ; Russel, N; Stark, A; Taylor, PR; Wood, K | 1 |
| Bollas, G; Dervenoulas, J; Economopoulos, T; Kalantzis, D; Koumarianou, A; Mantzios, G; Papageorgiou, E; Raptis, S; Rontogianni, D; Tsirigotis, P | 1 |
4 review(s) available for epirubicin and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Duodenum; Epirubicin; Fatal Outcome; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Pyrazines; Remission Induction; Stomach; Thalidomide; Tomography, X-Ray Computed; Vincristine | 2014 |
De novo CD5-positive diffuse large B-cell lymphoma of the temporal bone presenting with an external auditory canal tumor.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bone Neoplasms; CD5 Antigens; Cyclophosphamide; Ear Canal; Ear Neoplasms; Epirubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab; Temporal Bone; Vincristine | 2006 |
[ALK-negative primary gastric anaplastic large cell lymphoma].
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Combined Modality Therapy; Epirubicin; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Peripheral Blood Stem Cell Transplantation; Protein-Tyrosine Kinases; Receptor Protein-Tyrosine Kinases; Remission Induction; Salvage Therapy; Stomach Neoplasms; Transplantation, Autologous | 2007 |
[Diffuse B-cell lymphoma associated with hemophagocytic syndrome].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Histiocytosis, Non-Langerhans-Cell; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisolone; Vincristine | 1998 |
19 trial(s) available for epirubicin and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Long-term results of the R-CEOP90 in the treatment of young patients with chemotherapy-naïve diffuse large B cell lymphoma: a phase II study.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Prednisolone; Rituximab; Treatment Outcome; Vincristine | 2014 |
Rituximab and dose-dense chemotherapy in primary testicular lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Epirubicin; Humans; Longitudinal Studies; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Rituximab; Survival Rate; Testicular Neoplasms; Vincristine | 2009 |
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINT
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Geriatric Assessment; Humans; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Multivariate Analysis; Neutropenia; Prednisone; Proportional Hazards Models; Prospective Studies; Rituximab; Treatment Outcome; Vincristine | 2012 |
Radiotherapy versus combined therapy in early stages with bulky disease aggressive malignant lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Radiotherapy, High-Energy; Remission Induction; Treatment Outcome; Vincristine | 2003 |
Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Humans; Life Tables; Lymphoma, Large B-Cell, Diffuse; Male; Mexico; Middle Aged; Neoplasm Staging; Prednisone; Prospective Studies; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome; Vincristine | 2004 |
High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Mitoxantrone; Prednisone; Prognosis; Transplantation, Autologous; Vincristine | 2005 |
The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Epirubicin; Etoposide; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Prednisone; Vincristine | 2006 |
A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Etoposide; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prednisone; Prognosis; Rituximab; Survival Analysis; Transplantation, Autologous; Vincristine | 2006 |
Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Survival; Epirubicin; Etoposide; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Prednisone; Quality of Life; Survival Rate; Time Factors; Treatment Outcome; Vinblastine; Vincristine | 2007 |
Rituximab and escalated chemotherapy in elderly patients with aggressive diffuse large-cell lymphoma: a controlled clinical trial.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Epirubicin; Humans; Immunotherapy; Lymphoma, Large B-Cell, Diffuse; Rituximab; Survival Rate; Treatment Outcome | 2007 |
Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14 +R) in high-risk diffuse large cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Rituximab; Survival Rate; Treatment Outcome; Vincristine | 2007 |
Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Radiation; Doxorubicin; Epirubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Prednisone; Prospective Studies; Vincristine; Vindesine | 1994 |
Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisone; Procarbazine; Prospective Studies; Treatment Outcome; Vincristine | 1994 |
In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: results of a phase II study of P/DOCE chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epirubicin; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Prednisone; Probability; Prognosis; Prospective Studies; Treatment Outcome; Vincristine | 1993 |
Dose escalation of epirubicin in the CEOP-BLEO regimen: a controlled clinical trial comparing standard doses for the treatment of diffuse large cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Survival Rate; Treatment Failure; Treatment Outcome; Vincristine | 1997 |
Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Epirubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lymphocyte Count; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Neutropenia; Prednisolone; Recombinant Proteins; Vincristine | 1997 |
Investigation of the molecular changes during chemotherapy in non-Hodgkin's lymphoma.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Female; Genes, bcl-2; Genes, Immunoglobulin; Humans; Immunoglobulin Joining Region; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplastic Cells, Circulating; Polymerase Chain Reaction; Prednisolone; Translocation, Genetic; Vincristine | 1998 |
CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Prognosis; Reproducibility of Results; Treatment Outcome; Vincristine | 1998 |
High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Recurrence; Salvage Therapy; Survival Rate; Treatment Outcome | 2001 |
20 other study(ies) available for epirubicin and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Interim and end-of-treatment PET-CT suffers from high false-positive rates in DLBCL: Biopsy is needed prior to treatment decisions.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Clinical Decision-Making; Confidence Intervals; Cyclophosphamide; Doxorubicin; Epirubicin; Etoposide; False Positive Reactions; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Multivariate Analysis; Positron Emission Tomography Computed Tomography; Prednisone; Proportional Hazards Models; Rituximab; Survival Rate; Treatment Outcome; Vincristine | 2021 |
Treatment of diffuse large B-cell lymphoma in elderly patients: Replacing doxorubicin with either epirubicin or etoposide (VP-16).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Substitution; Epirubicin; Etoposide; Female; Follow-Up Studies; Heart Diseases; Humans; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Matched-Pair Analysis; Prednisone; Progression-Free Survival; Retrospective Studies; Rituximab; Vincristine | 2019 |
Use of epirubicin to treat diffuse large B-cell lymphoma.
Topics: Adult; Anthracyclines; Child; Epirubicin; Humans; Lymphoma, Large B-Cell, Diffuse | 2019 |
Epirubicin inhibits soluble CD25 secretion by Treg cells isolated from diffuse large B-cell lymphoma patients.
Topics: Antibiotics, Antineoplastic; Apoptosis; Case-Control Studies; Enzyme-Linked Immunosorbent Assay; Epirubicin; Flow Cytometry; Humans; Interleukin-2 Receptor alpha Subunit; Leukocytes, Mononuclear; Lymphoma, Large B-Cell, Diffuse; T-Lymphocytes, Regulatory; Tumor Cells, Cultured | 2013 |
Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Female; Gene Expression; Humans; Immunophenotyping; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Prednisone; Prognosis; Proto-Oncogene Proteins c-bcl-2; Retrospective Studies; Rituximab; Treatment Outcome; Vincristine | 2014 |
Rituximab as consolidation therapy did not improve outcome in patients with diffuse large B-cell lymphoma at complete response after dose-dense chemotherapy (CHOP-14).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Prednisone; Prognosis; Remission Induction; Rituximab; Survival Rate; Vincristine; Young Adult | 2015 |
Primary B cell lymphoma of the tongue base: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Prednisone; Rituximab; Tongue Neoplasms; Vincristine | 2016 |
[The value of radiotherapy in the treatment of aggressive and localised gastric lymphomas].
Topics: Academic Medical Centers; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Patient Selection; Prednisone; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Stomach Neoplasms; Survival Rate; Treatment Outcome; Tunisia; Vincristine | 2009 |
Incidence and outcome of patients with diffuse large B cell lymphoma with marrow involvement and preliminary experience of an adult acute lymphoblastic leukemia protocol (NEALL VI) in cyclophosphamide, doxorubicin, vincristine, and prednisolone--rituximab
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Humans; Idarubicin; Ifosfamide; Incidence; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Mitoxantrone; Prednisolone; Prognosis; Registries; Retrospective Studies; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome; Vincristine | 2009 |
[Tunisian experience in the treatment of aggressive non Hodgkin's lymphoma in adults: about 337 patients].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epirubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Karnofsky Performance Status; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Prednisone; Prospective Studies; Remission Induction; Rituximab; Stem Cell Transplantation; Survival Analysis; Tunisia; Vincristine; Young Adult | 2010 |
Cardiotoxicity in patients treated with bevacizumab is potentially reversible.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Labeling; Early Termination of Clinical Trials; Epirubicin; Female; Fluorouracil; Heart Failure; Humans; Lymphoma, Large B-Cell, Diffuse; Meta-Analysis as Topic; Paclitaxel; Prednisone; Razoxane; Remission, Spontaneous; Rituximab; Trastuzumab; Vincristine | 2011 |
Prognostic value of platelet count in diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Multivariate Analysis; Neutropenia; Platelet Count; Prednisolone; Prognosis; Retrospective Studies; Rituximab; Thrombocytopenia; Treatment Outcome; Vincristine; Young Adult | 2012 |
Primary bone lymphoma of the shoulder.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Diabetes Mellitus, Type 2; Epirubicin; Female; Humans; Humerus; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Middle Aged; Osteolysis; Prednisolone; Radiography; Rituximab; Vincristine | 2012 |
Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for refractory or early relapsing patients with aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Epirubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Salvage Therapy; Transplantation, Autologous; Treatment Outcome | 2004 |
The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Cycle; Cohort Studies; Cyclin-Dependent Kinase Inhibitor p21; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Female; Genes, p53; Germinal Center; Humans; Immunohistochemistry; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Proteins; Phenotype; Prednisone; Prognosis; Radiotherapy, Adjuvant; Reproducibility of Results; Rituximab; Survival Analysis; Survival Rate; Tumor Suppressor Protein p53; Vincristine | 2006 |
Therapy for older patients with diffuse large cell lymphoma: targeting the treatment to the patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Survival; Epirubicin; Etoposide; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Prednisone; Treatment Outcome; Vinblastine; Vincristine | 2007 |
Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Fatal Outcome; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Immunophenotyping; Immunotherapy; Lymphatic Irradiation; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasm Recurrence, Local; Prednisone; Rituximab; Stomach Neoplasms; Vincristine | 2007 |
[CEOP regimen in the treatment for non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Middle Aged; Neoplasm Staging; Neutropenia; Prednisone; Remission Induction; Retrospective Studies; Survival Analysis; Thrombocytopenia; Vincristine | 2007 |
Complete cure of malignant lymphoma of the stomach with a huge adrenal lesion achieved by preoperative chemotherapy and surgery: report of a case.
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Gastrectomy; Humans; Infusions, Intravenous; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Neoadjuvant Therapy; Prednisolone; Stomach Neoplasms; Treatment Outcome; Vincristine | 2001 |
T-cell-rich B-cell lymphoma. Analysis of clinical features, response to treatment, survival and comparison with diffuse large B-cell lymphoma.
Topics: Aged; Antigens, CD; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Female; Humans; Immunohistochemistry; Liver; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisolone; Prednisone; Retrospective Studies; Spleen; Survival Rate; T-Lymphocytes; Time Factors; Vincristine | 2001 |